Resources

Added to site: January 5, 2022 Chimeric antigen receptor T-cell therapy: An emergency medicine focused review

Added to site: January 5, 2022 Immune checkpoint inhibitors: An emergency medicine focused review

Added to site: September 22, 2021 Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward

Added to site: September 13, 2021 Study shows stem-like T cells could aid immunotherapy in cancer treatment

Added to site: September 13, 2021 Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer

Added to site: September 13, 2021 Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis

Added to site: September 13, 2021 The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

Added to site: September 13, 2021 What makes immunotherapies successful in one tumor but not in others?

Added to site: July 6, 2021 Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Added to site: April 12, 2021 Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses

Added to site: April 12, 2021 Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Added to site: April 12, 2021 Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin Cancers

Added to site: April 12, 2021 Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies

Added to site: April 8, 2021 Fecal Transplant Boosts Cancer Immunotherapy

Added to site: April 8, 2021 Immuno-antibiotics: Targeting microbial metabolic pathways sensed by unconventional T cells

Added to site: April 6, 2021 Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Added to site: April 6, 2021 Immunotherapy of advanced melanoma with immune checkpoint inhibition

Added to site: April 6, 2021 Special Considerations in Adults and Children With Cancer

Added to site: April 6, 2021 COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Added to site: April 6, 2021 Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

Added to site: April 6, 2021 Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Added to site: April 6, 2021 Combination Immunotherapy and BRAF/MEK Inhibitor Therapy for BRAFV600-Mutated Advanced Melanoma: Are We There Yet?

Added to site: November 24, 2020 Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Added to site: September 21, 2020 Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types

Added to site: August 13, 2020 Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

Added to site: July 21, 2020 Association of Anti–Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

Added to site: July 2, 2020 Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes

Added to site: May 26, 2020 Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database

Added to site: April 28, 2020 Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

Added to site: April 14, 2020 Autoimmune complications of immunotherapy: pathophysiology and management

Added to site: April 14, 2020 Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

Updated on: December 17, 2019 Common Terminology Criteria for Adverse Events (CTCAE), version 5.0, 2017

Updated on: December 17, 2019 National Comprehensive Cancer Network (NCCN) practice guidelines. Management of immunotherapy-related toxicities, Version 1.2020.

Added to site: September 24, 2019 High expression of RIG-I DDX58 in human melanoma correlates with prolonged survival and durable responses to anti–CTLA-4 immunotherapy

Added to site: August 12, 2019 Precision Medicine

Added to site: July 22, 2019 Immunotherapy: What It Is, How It Works, and Current Research

Added to site: July 22, 2019 In a small study, a cancer vaccine assist beats immunotherapy drugs alone

Added to site: July 22, 2019 Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features

Updated on: July 8, 2019 Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors

Added to site: June 28, 2019 8 important updates for Cancer Immunotherapy Month

Added to site: June 28, 2019 Practice, Preferences, and Practical Tips From Primary Care Physicians to Improve the Care of Cancer Survivors

Updated on: June 26, 2019 Survivorship 2.0

Updated on: April 11, 2019 Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination

Added to site: March 22, 2019 New Rheumatology Emphasis on Immune-related Adverse Events (irAEs)

Updated on: February 19, 2019 Using CTCAE to Report Immunotherapy Adverse Events

Updated on: February 5, 2019 Immune Checkpoint Inhibitor Toxicity in 2018

Updated on: January 29, 2019 Cancer immunotherapy regimens and clinical features of inflammatory arthritis

Updated on: January 14, 2019 Immunotherapy 2.0: Improving the Response to Checkpoint Inhibitors

Added to site: December 14, 2018 Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches

Updated on: December 14, 2018 Best Practices for Implementing Cancer Immunotherapy in the Community

CATALYST: Immuno-Oncology Resource Center

Added to site: June 17, 2020 ASCP Immuno-Oncology Scientific Updates Webcast: Tumor Mutational Burden (PDF)

Updated on: January 27, 2020 Top 10 Challenges in Cancer Immunotherapy

Added to site: December 2, 2019 A 3D Tour of Immuno-Oncology

Added to site: December 2, 2019 A 3D Tour of Immuno-Oncology

Added to site: June 28, 2019 Watch and Learn – "Immuno-Oncology: A Future Look" Event Video Recording

Updated on: June 5, 2019 TUMOUR MUTATION

Updated on: June 5, 2019 BIOMARKERS

Updated on: June 5, 2019 ADVERSE EVENTS

Updated on: May 10, 2019 UKONS Acute Oncology Initial Management Guidelines

Updated on: February 19, 2019 IC-ONC Resources PDF

Updated on: February 5, 2019 Clinical Advances in Cancer Immunotherapy

Updated on: February 5, 2019 A 3D Tour on Immuno-Oncology

Updated on: February 5, 2019 NCCN Guidelines®

Added to site: December 14, 2018 Immuno-Oncology Updates

Added to site: May 25, 2021 Immune cellular functions and cytokine effects on tumorigenesis

Added to site: May 25, 2021 Complementary antitumor effects of immunotherapy and chemotherapy in NSCLC

Added to site: April 13, 2021 Exploring irAEs

Added to site: June 17, 2020 Immuno Oncology Scientific Updates Webcast Tumor Mutational Burden

Updated on: April 16, 2020 ASCP Tumor Board Simulation - Immune-Related Adverse Events

Updated on: December 17, 2019 Cancer and the Immune System

Updated on: December 5, 2019 Immune Checkpoint Blockade

Added to site: January 23, 2019 Immune Related Adverse Events